Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)

Key facts

Sponsor

The Hospital for Sick Children

Principal Investigator

Joe T Clarke, MD

The Hospital for Sick Children

Intervention

Pyrimethamine(drug)

Enrollment

20 enrolled

Eligibility

17 years · All sexes

Timeline

2009 – 2010

Study locations (1)

• The Hospital for Sick Children, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gangliosidosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07082543
  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
  Azafaros A.G.
• RECRUITINGPHASE1, PHASE2NCT03952637
  A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
  National Human Genome Research Institute (NHGRI)
• RECRUITINGNCT00668187
  A Natural History Study of the Gangliosidoses
  University of Minnesota

See all trials for Gangliosidosis →